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ABSTRACT
Eukaryotic genomes transcribe up to 90% of the genomic DNA but only 1–2% of these transcripts encode for proteins, where-
as the vast majority are transcribed as non-coding RNAs (ncRNAs). They are divided into short ncRNA, particularly micro-
RNA (miRNA) and small interference RNA (siRNA), and long ncRNAs. Noteworthy, they are unexpectedly stable since they 
are protected from degradation through different mechanisms: package in exosomes/microvesicles structures, in apoptotic 
bodies, in HDL lipoprotein, or by RNA binding proteins. For several years already, biomarkers have been used to detect bio-
logical disease; in the last years, a requirement appeared to find some of them to unearth the signs of doping. The potential of 
ncRNAs as a biological candidate is strongly debated and it seems to have become the right tool in the anti-doping hands. In 
the recent years, the next-generation sequencing (NGS) technology was used by the World Anti-Doping Agency to draft the 
athlete biological passport (ABP), measuring the circulating miRNAs and applying these new biomarkers in anti-doping. NGS 
technology does not require any prior knowledge of ncRNAs, but the limit to employ this biomarker to detect performance-
enhancing drug use must consider the intrinsic and extrinsic factors that might affect measurements.
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Introduction
Epigenetics is the study of those heritable changes in 
gene expression which do not cause changes in the pri-
mary sequence of DNA [1]. The main feature of epige-
netic changes is that they can be copied from one genera-
tion to another, causing, in the long run, even changes in 
the phenotype.
Epigenetic changes determine the uniqueness of a par-
ticular phenotype through the expression of certain genes 
and repression of others. It is expressed by means of 
chromatin modification or by covalent modifications 
of histones that include acetylation and methylation of 
lysine residues, acetylation and phosphorylation of tyros-
ine residues, histidine phosphorylation, etc. The methyl-
ation processes may occur even after the replication to 
work of methyltransferases, causing the silencing or ac-
tivation of particular genes via, respectively, hypermethyl-
ation and hypomethylation [2].
Many regulatory proteins bring epigenetic tags; these 
cause transcriptional changes of the genome. For exam-
ple, the family of DNMT enzymes, DNA-methyltran-
ferases (DNA MTase), determine DNA methylation of 
a cytosine at the 5’ position. There are also lysine methyl-
transferases (HMTase) that add methyl groups to lysine 
residues in histones.
Other epigenetic regulators of particular importance 
were found to be the non-coding RNA (ncRNA) acting 
both at the transcriptional and translational level and 
play a crucial role in the formation of heterochromatin 
or silencing of certain genes.
They are divided into:
– short ncRNA, of which the best known are mi-
croRNA (miRNA) and small interference RNA (siRNA);
– long ncRNAs (lncRNA).
Several studies show that 90% of the human genome 
is transcribed, mostly as ncRNAs [3, 4]. The ncRNA are 
ranked housekeeping and regulatory on the basis of 
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their function: the former are always expressed, while 
the latter are regulators of gene expression. The house-
keeping ncRNA are snRNA (small nuclear), mRNA, 
tRNA, snoRNA (small nucleolar RNA). The regulato-
ry ncRNA, with regard to their size, are classified into 
longer and short. When the molecule is composed of less 
than 200 nucleotides, it is called small ncRNA; these 
include miRNAs, Piwi-associated RNA (piRNAs) and 
siRNAs. If it is composed of more than 200 nucleo-
tides, it is called long ncRNAs [5–7].
The lncRNA are classified into groups and subgroups, 
for example sense-RNAs when one or more exons over-
lap to another one transcribed on the same strand; in-
tronic-RNA when derived from an intron; intergenic-
RNA when localized between two genes [8]. Other groups 
are 3’-UTR associated RNAs that derive from 3’-untrans-
lated regions of protein-coding transcript and TERRA’s 
group, including telomeres, telomeric repeat-containing 
RNA [9].
These molecules are involved in numerous biologi-
cal processes and in organizing chromatin to proteins 
[10, 11]. LncRNAs regulate the modifications of chro-
matin, transcription and post-transcriptional processes; 
moreover, they are involved in epigenetic reprogramming 
of specific sites and in maintaining molecular stoichiom-
etry [12]. The lncRNA are able to remodel chromatin and 
histones and are also involved in alternative splicing [13].
The lncRNAs are expressed even in the central nerv-
ous system where they play an important role in the con-
trol of gene expression during development and are in-
volved in the differentiation of neurons and in their 
destiny [14, 15].
The brain-derived neurotrophic factor (BDNF) is es-
sential for synaptic plasticity, for memory, and for neu-
ronal growth. An anti-BDNF (BDNF-AS) lcnRNA has 
been discovered that could constitute duplex dsRNA with 
BDNF mRNA in the brain [16]. Failure in the function-
ality of BDNF-AS determines the onset of neurite for an 
increased concentration of BDNF mRNA and protein.
Different studies have shown the involvement of 
lcnRNA in neurological disorders such as Alzheimer’s 
disease [17], Parkinson’s disease, neuroimmunological 
disorders [18], Huntington’s disease, neuro-oncological 
disease. For this reason, these molecules could be used 
as targets for the treatment of the above pathologies, and 
several studies are still being performed in both animals 
and humans.
The ncRNA
In a classical view, RNA plays the fundamental role 
of an intermediate stream of genetic information from 
DNA to the final protein product, while in the light of the 
latest advances in molecular biology, aimed at under-
standing the cell system, profound revisions of this way 
of thinking are necessary. Historically, RNA has been 
characterized and formally divided into different classes 
on the basis of different properties and functions: the 
messenger RNA (mRNA) undergoes the process of trans-
lation by the ribosome for protein synthesis; the ribo-
somal RNA (rRNA) is essential for the assembly of ribo-
somal proteins, therefore playing a structural function, 
and for the link with mRNA; the transfer RNA (tRNA) 
is involved in the process of protein synthesis as trans-
porting into the A site of the ribosome amino acids to 
be incorporated into the nascent polypeptide chain. 
Actually, in the recent years, a number of additional 
biological functions of RNA have been identified, not 
only in structural quality and as molecules with catalytic 
activity, but also – and especially – as regulators of gene 
expression in various cellular processes, like differen-
tiation, development, or oncogenesis.
Less than 1.5% of the mammalian genome encodes 
proteins, about 5% is preserved, and recent large-scale 
studies have shown that most of the genome is tran-
scribed in a complex repertoire of overlapping transcripts, 
often from both strands of DNA.
A significant part of these transcripts are processed 
in small and long RNA regulators [19], acting through 
a specific recognition sequence of other RNA or DNA 
to promote the development of several programs by 
modulating the structure of RNA, splicing and stability, 
transcription and translation, as well as chromatin 
structure [20].
The lncRNA
There are tens of thousands of lncRNAs, polyade-
nylated and non-transcribed from the mammalian ge-
nome [21, 22], many of which appear to be regulated 
during development, subjected, alternatively spliced, 
inducible under physiological conditions [23, 24].
A set of these lncRNAs is defined as macroRNA, 
transcribed by long non-coding regions expressed in 
mice; many of them are enriched in the brain, they have 
transcription antisense, and seem localized mainly in 
the nucleus [25].
It is known that thousands of lncRNAs are encoded 
in the human genome, expressed mostly in tissue-spe-
cific patterns, and pairing with DNA, other RNAs and 
proteins with a various mechanisms of action [26].
Many classes of ncRNAs are involved in the devel-
opment of dendrites, transport and localization of mRNA, 
and local protein synthesis [27]. The central component 
of these processes is a protein that binds RNA, fragile X 
mental retardation protein (FMRP), the absence of which 
causes mental retardation, epilepsy, autism, and disor-
ders related to anxiety. FMRP is part of an elaborate ribo-
nucleoprotein complex which also includes FXR1P/2P, 
nucleolin, YB1/p50, Pur , Staufen, IMP1 and kinesin 5, 
and ncRNA BC1 and BC200, preserved in the mouse 
and in humans.
In Drosophila, lncRNAs are involved in many stages 
of organogenesis and cell differentiation; showing a rapid 
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evolution, they are expressed during embryogenesis and 
are highly specific for the central and peripheral nervous 
system [23].
In mammals, lncRNAs also come from natural an-
tisense transcripts [28], many of which are abundant in 
the nervous system, with expression profiles defined 
in the development and in different areas, and modulate 
the expression of genes involved in the morphogenesis 
of the brain, the proliferation of stem cells, stress re-
sponse, cell polarity, cytoskeletal functions, neuronal 
survival, maturation, and synaptic plasticity [29].
Finally, lncRNAs are able to modulate mRNA levels 
by competing for miRNA binding [30].
The miRNA
These are fragments of about 21–25 nucleotides of 
single-stranded ncRNAs; they are able to repress the 
translation or to cause degradation of the target mRNA 
or can regulate the gene expression at the post-tran-
scriptional level. Each miRNA can regulate different 
genes. It is known to be involved in the regulation of 
various cell functions and their alterations are impli-
cated in various pathological processes. The term ‘micro 
RNA’ was introduced in 2001 [31]. Thousands of miR-
NAs have been identified in humans and other species 
[32], and several databases which could be consulted 
now exist. Biogenesis of miRNA is a process that starts in 
the nucleus with the transcription by RNA polymerase II 
to form long primary transcripts called ‘primiRNAs’ 
that are capped (5’end) and polyadenylated (3’end), ap-
proximately of 70 nucleotides with the typical hairpin 
structure. PrimiRNAs are processed by a complex con-
taining RNAse endonuclease III Drosha and DGCR8 
(DiGeorge syndrome critical region gene 8). By process-
ing, a 60–120-nucleotide long miRNA precursor (pre-
miRNA) was obtained. Later, it is transferred from the 
nucleus to the cytoplasm by exportin-5 in the presence 
of a GTP-binding nuclear protein Ran (RanGTP). There, 
the final cleavage was made by the RNAse III enzyme 
Dicer that interacts with the 5’- and 3’ends of the hairpin 
and cuts the extremities, eliminating the stem-loop and 
producing a mature double stranded miRNA of about 
22 nucleotides. Finally, one strand is normally deleted 
and the other is incorporated into the RNA-induced si-
lencing complex (RISC). Here, miRNAs interact selec-
tively with Argonaute proteins, a riboproteic complex 
responsible for the selection process of the filament 
guide and for the degradation of the complementary 
strand. Finally, within RISC, the mature single-stranded 
miRNA interacts with the target mRNA, most frequently 
with the 3’ untranslated region [33–35]. The function 
of the miRNA is obtained when it finds its cognate RNA 
and pairs with it. This will involve a different action, 
depending on the degree of complementarity. In plants, 
there is a perfect pairing between miRNA and mRNA 
that promotes the degradation of the messenger; in 
animals, in turn, the pairing is imperfect and involves 
few nucleotides: 2–7 or 2–8 of the miRNA [36]; this can 
lead to mRNA cutting, degradation, or repression of trans-
lation. The miRNAs are able to bind not only 3’UTR of 
their target transcripts, but also other regions, like 5’UTR, 
promoter, and open reading frames [37]. Another im-
portant effect of the action of miRNAs is that one mRNA 
can be modulated by numerous miRNAs, suggesting the 
possibility of miRNA cooperative repression. The miRNAs 
regulate up to one-third of human genes participating 
in various biological processes, like cell proliferation, dif-
ferentiation, cell cycle regulation, apoptosis, hematopoie-
sis, and hypoxia. The alterations of the normal pathway 
of miRNA expression may have consequences for nor-
mal cell physiology and lead to various types of diseases, 
including inflammatory conditions [35].
The siRNA
The siRNA is considered a double-stranded RNA of 
about 21–22 nucleotides, previously thought to be of 
exogenous origin, for example viruses. It typically binds 
perfectly to its mRNA target; it is a perfect match to 
the sequence like previously described in plants, and 
leads to mRNA degradation. The siRNA protects the in-
tegrity of the genome from nucleic acids strangers or 
invasion, and can be generated from long dsRNA mole-
cules resulting from the replication of RNA viruses 
(vsiRNAs) [38] or from mobile transposable elements 
(endo-siRNAs) [39–42], or may be produced syntheti-
cally by transgenes expressing dsRNA molecules.
The piRNA
A major study is taking place on piRNA (Piwi-asso-
ciated RNA) or non-coding strands of RNA consisting of 
24–30 nucleotides, which, like miRNAs, interact with 
a different class of Argonaute proteins, Piwi, and, for 
their biogenesis, are independent of the Dicer. The pi-
RNA primarily derives from transposons and other 
repetitive elements. Genetic studies indicate that piRNAs 
are very important in the development of the germ line, 
and proteins involved in the production of piRNA are 
employed in the regulation of gene expression in somatic 
cells, in learning and memory, suggesting that piRNA 
could have a very important role in different biological 
processes.
The altered expression of miRNAs is sometimes due 
to chromosomal rearrangements or epigenetic events, 
so it is essential to study miRNAs in the context of their 
genomic location so that one can find correlations be-
tween their aberrant expression and a specific disease 
[43, 44]. There are a number of activities underway to 
map all the miRNA and piRNA genes at fragile sites, in 
areas where there are repetitive elements and in CpG 
islands and SNP, to see the effect of the two groups of 
ncRNA in fragile sites and similarities or differences 
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in their distribution in the individual human chromo-
somes. Simultaneously, there is an analysis in progress 
to analyse their distribution in the human genome, and 
a public database is now present [45].
The circRNA
RNA versatility seems limitless, the latest surprise 
being the circular RNA (circRNA), which works by coun-
teracting miRNAs; inhibition by miRNAs of the trans-
lation can be suppressed by circRNA that are able to 
bind many copies of a miRNA, allowing translation of 
mRNA. The circRNAs are very stable, quite conserved, 
and their genes are widely represented in the genome [46]; 
indeed, their number exceeds that of protein-coding 
genes. They are derived from the splicing of an exon and 
the subsequent fusion of the 5’ with its 3’ or that of a fur-
ther upstream exon. The fact of being circular gives it 
a high stability because having no free ends, they can-
not be degraded by the exonuclease [47, 48].
The circRNAs serve as reservoirs of miRNAs that 
bind with greater affinity than the mRNA, so they were 
defined as miRNA sponge [49]. Moreover, recent study 
hypothesize that they can also bind different proteins 
(RBP ribonucleoproteins) and sequester them in the cyto-
plasm [48]; prevent them from acting, perhaps provide 
a protective reservoir of these molecules; deliver factors 
to particular subcellular locations; or act as scaffolds 
for the assembly of other complexes [50].
Circulating miRNA
While the biogenesis of miRNA is an intracellular 
process, it is now clear that these molecules are released 
from cells in the environment and can be internalized 
from recipient cells where they can alter gene expression 
either in physiological or in pathological conditions [51].
The extracellular miRNAs represent a new form of 
intercellular communication through the transfer of 
genetic information. They are found in many biological 
fluids, such as plasma, serum, saliva, urine, tears, breast 
milk [52–55].
The extracellular miRNAs are unexpectedly stable; 
they must be protected from degradation because the 
naked RNA is readily targeted by exonuclease, abun-
dantly present in many extracellular fluids. So, miRNAs 
are packed with different mechanisms: exosomes/mi-
crovesicles (MVs), apoptotic bodies, RNA binding pro-
teins, HDL, and lesser, LDL [52].
Exosomes are extracellular vesicles (40–120 nm) that 
originate from multi-vesicular bodies (MVBs) and are re-
leased by exocytosis of these MVBs. They are produced 
by many cell types, have been identified in many circu-
lating fluids, and may serve as a carrier of miRNAs [56].
MVs, another form of vesicles, are larger than exo-
somes (100 nm–1 μm) and derive from the plasma mem-
brane of a large variety of cells. The presence of miRNAs 
in the MVs was described in 2008 [57].
Exosomes and MVs are now recognized as a funda-
mental way for cell-to-cell horizontal transfer of proper-
ties, in both physiological and pathological conditions. 
Cancer cells use extracellular vesicles (EV) to discard mol-
ecules which could be dangerous to them (e.g. differen-
tiation-inducing proteins such as histone H1.0, or an-
titumor drugs [58]), to transfer molecules which, after 
entering the recipient cells, are able to transform their 
phenotype, and even to secrete factors (i.e. RNA, his-
tones, RBPs) which allow escaping from immune sur-
veillance [59].
Apoptotic cells release extracellular membrane vesi-
cles into the environment; apoptotic bodies are large 
particles (1–5 μm) with a heterogeneous form. For in-
stance, in atherosclerosis, endothelial cells produce apop-
totic bodies enriched in mir-126 and containing other 
minor miRNAs. This brings the acceptor cells to pro-
duce a chemokine which limits atherosclerosis, leads to 
plaque stability, and causes recruitment and prolifera-
tion of endothelial progenitor cells [60].
A significant fraction of miRNAs is associated with 
extracellular proteins that bind RNA and protect it 
from degradation, like the family of Argonaute proteins, 
Ago 2 [61].
Finally, extracellular miRNA can also be carried by 
HDL and, in lesser amounts, by LDL, participating in the 
mechanism of intercellular communication [52, 62, 63].
Biomarkers for detection of doping in sport
For several years already, biomarkers have been used 
to detect biological disease; in the last years, a require-
ment appeared to find some of them to unearth the signs 
of doping. The potential of ncRNAs as a biological can-
didate is strongly debated and it seems to have become 
the right tool in the anti-doping hands. Although the way 
to act is similar, some may have effect on the expression 
of any genes by inducing interference, some other – on 
the degradation of mRNA (e.g. siRNA) [64]. An example 
of RNA interference aiming at performance enhance-
ment in elite sports is the block of the myostatin gene: it 
has been demonstrated in mice that the latter is a muscle-
growth inhibitor [65] and its down-regulation by an an-
tisense oligonucleotide results in an increased growth 
of the leg muscle [66]. If myostatin is a negative regu-
lator of proliferation, insulin growth factor-1 (IGF-1) 
induces satellite cells proliferation and is stimulated 
from growth hormone (GH), another widespread doping 
agent. Since the real problem is to discriminate between 
endogenous and exogenous GH, it is used to detect the 
abuse by an indirect method based on the evaluation 
of IGF-1 level [67]. All the strategies applied to charac-
terize siRNA in biological fluids are comparable to an 
experimental ‘RNomics’ approach, which may help as 
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a potential link between genome and proteome in the 
next future [68]. Also called antagomirs, they repre-
sent a new strategy that could play an important role 
in doping control. The antagomirs block the action of 
endogenous miRNA, increasing the expression of cer-
tain target genes. One of the most prominent exam-
ples is represented by the myostatin gene, which cur-
rently has the highest potential for misuse in sport, 
given the numerous investigations in drug research. 
The downregulation of this gene has been shown to 
induce an improvement in performance and an in-
crease in muscle mass [69].
Although most RNA molecules are unstable, circu-
lating miRNAs are highly stable, probably because they 
are protected in exosomes and microparticles, and readily 
detectable in body fluids such as urine, saliva, and plasma 
[70, 71]; alternatively, circulating miRNAs may be asso-
ciated with specific protective proteins. Many advanced 
technologies have to setup to miRNA-profiling and to 
detect any change in concentration [54]. The most widely 
used approach is the quantitative reverse transcription 
(qRT)-PCR, which remains the most sensitive and re-
liable method for detecting circulating miRNAs. Usu-
ally this method needs to validate the results from the 
first screening performed by microarray. Most of the 
existing tools (e.g., qRT-PCR and microarray) offer high 
sensitivity and specificity in ncRNA research: they are 
able to accurately detect a wide spectrum of selected 
ncRNAs and require prior knowledge of the sequence of 
interest to design primers. Among the various methods 
available to isolate exosomes before performing down-
stream analysis such as microarrays or qRT-PCR, the 
most innovative is the next-generation sequencing 
(NGS). The NGS technology does not require any pri-
or knowledge of ncRNAs and thus it allows all ncRNA 
species to be sequenced in a high throughput manner [72]. 
In the last years, this approach was applied to draft the 
athlete biological passport (ABP), measuring the circu-
lating miRNAs with the use of these new biomarkers in 
anti-doping [73]. The limit to employ this biomarker to 
detect performance-enhancing drug use must consider 
the intrinsic and extrinsic factors that might affect meas-
urements. In addition, the influence of confounding fac-
tors such as gender, age, high altitude, or physical exercise 
remains to be determined [74]. In fact, a study reported 
the circulating miRNAs as biomarkers of exogenous tes-
tosterone administration; it showed a variation in the 
expression of two of the miRNAs analysed (miR-150 and 
miR-342, mainly expressed in white blood cells, and 
miR-150, particularly abundant in mature B and T lym-
phocytes) but when compared with the control samples, 
the change was testosterone-independent [75]. Thus, 
changes are not determinable and seem to be subject-de-
pendent; this highlights a significant weakness of the 
method. With regard to one of the most widespread 
doping practices, blood doping, it represents one of the 
most effective methods used to improve the athletic per-
formance in aerobic sports. The WADA has developed 
strategies for their detection methods based on both 
direct and indirect way. The direct method mainly con-
cerns the identification of the use of recombinant human 
erythropoietin (rHuEPO), which stimulates red blood 
cell production. The rHuEPO detection methods cur-
rently exist, including measurement of hematologic param-
eters, use of peptide markers, isoelectric focusing (IEF) 
double immunoblotting, aptamer/antibody based meth-
ods [76]. The indirect methods are used in order to high-
light e.g. the autologous blood transfusion. Schumacher 
and Pottgiesser [77] already revealed that the haemo-
globin concentration had a significant variability, depend-
ent on the different phases of the day or the exercise 
performed [78]. This is the principle of the ABP, which 
represents a milestone in the doping control. Actually 
other approaches of indirect methods are based on 
OMICS-sciences (in which ncRNA transcriptomics are 
the landmark) or on the detection of metabolites in urine 
samples, for example the 2-ethylhexylphthalate, a me-
tabolite excreted as a result of autologous blood trans-
fusion [79].
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